Hasil Pencarian  ::  Simpan CSV :: Kembali

"STEMI adalah IMA dengan risiko mortalitas tinggi. Risiko dikurangi dengan revaskularisasi berupa IKPP Gangguan kardiovaskular dikaitkan dengan penurunan konsentrasi vitamin D. Penurunan bisa disebabkan SNP gen CYP27B1 yang mengkode enzim 1α hidroksilase dan belum ada penelitian yang menghubungkan konsentrasi vitamin D pada pasien STEMI yang menjalani IKPP. Hasil IKPP berupa area sumbatan dan kemampuan darah mengalir ke pembuluh darah koroner, dikenal dengan TIMI grade 0-3. Penelitian bertujuan untuk menganalisis hubungan konsentrasi kalsidiol dan gen CYP27B1 (-rs10877012) perubahan G ke T pada pasien STEMI yang menjalani IKPP dengan aliran TIMI akhir. Seratus subjek STEMI dan kontrol diambil 3 mL darah. Plasmanya diukur konsentrasi kalsidiol dengan teknik ELISA. PBMC dianalisis gen CYP27B1 (- rs10877012) dengan qRT PCR teknik Taqman Probe. Data dianalisis statistik kemaknaan 0,05. Konsentrasi kalsidiol median kasus 35,94 ng/ml dan kontrol 20,89 ng/ml berbeda bermakna (p=0,0001). Variasi gen CYP27B1 pada kedua kelompok berbeda bermakna (p=0,0001), dengan polimorfisme TT kasus 28% dan kontrol 19%. Hubungan konsentrasi kalsidiol dengan polimorfisme gen CYP27B1 berbeda bermakna (p=0,0001), tidak terdapat hubungan konsentrasi kalsidiol dengan aliran TIMI dan polimorfisme gen CYP27B1 dengan p=0,232. Konsentrasi kalsidiol tinggi pada kasus dimungkinkan sebagai respon tubuh terhadap inflamasi yang mengalami serangan jantung. Polimorfisme TT kasus 28% tidak memiliki hubungan terhadap patofisiologi aliran TIMI akhir.......STEMI is an AMI with a high risk of mortality. The risk is reduced by revascularization called by IKPP Cardiovascular disorders are associated with decreased vitamin D concentrations. The decrease could be due to the SNP gene CYP27B1 which encodes the enzyme 1α hydroxylase and no studies have linked vitamin D concentrations in STEMI patients undergoing IKPP. IKPP results in the form of block area and the ability of blood to flow to the coronary blood vessels, known as TIMI grade 0-3. The aim of this study was to analyze the relationship between calcidiol concentrations and the CYP27B1 gene (-rs10877012) G to T changes in STEMI undergoing IKPP with TIMI flow. One hundred STEMI and control subjects collected 3 mL of blood. Plasma concentration of calcidiol was measured using the ELISA technique. PBMCs were analyzed CYP27B1 gene (- rs10877012) by taqman probe qRT PCR. Data were analyzed by statistical significance of 0.05. Median calcidiol concentration of 35.94 ng / ml cases and 20.89 ng / ml controls was significantly different (p = 0.0001). CYP27B1 gene variation in the two groups was significantly different (p = 0.0001), with TT polymorphism of 28% and 19% of controls. The correlation between calcidiol concentration and CYP27B1 gene polymorphism was significantly different (p = 0.0001), there was no correlation between calcidiol concentration and TIMI flow and CYP27B1 gene polymorphism with p = 0.232. The high calcidiol concentration in this case may be the body's response to inflammation following a heart attack. The TT polymorphism of 28% cases had no relationship to the pathophysiology of late TIMI flow."

"ABSTRACTBackground: to identify other factors other than the TIMI scores that can be used as predictors of 30-day mortality in STEMI patients by including variables of left ventricle ejection fraction (LVEF) and glomerulus filtration rate (GFR) at Cipto Mangunkusumo National Central General Hospital. Methods: a retrospective cohort study was conducted in 487 STEMI patients who were hospitalized at RSUPN Cipto Mangunkusumo between 2004 and 2013. Sample size was calculated using the rule of thumbs formula. Data were obtained from medical records and analyzed with bivariate and multivariate method using Coxs Proportional Hazard Regression Model. Subsequently, a new scoring system was developed to predict 30-day mortality rate in STEMI patients. Calibration and discrimination features of the new model were assessed using Hosmer-Lemeshow test and area under receiver operating characteristic curve (AUC). Results: bivariate and multivariate analyses showed that only two variables in the new score system model were statistically significant, i.e. the Killip class II to IV and GFR with a range of total score between 0 and 4,6. Thirty-day mortality risk stratification for STEMI patient included high, moderate and low risks. The risk was considered high when the total score was >3,5 (46,5%). It was considered moderate if the total score was between 2,5 and 3,5 (23,2%) and low if the total score was <2,5 (5,95%). Both variables of the score had satisfactory calibration (p > 0,05) and discrimination (AUC 0,816 (0,756-0,875; CI 95%). Conclusion: There are two new score variables that can be used as predictors of 30-day mortality risks for STEMI patients, i.e. the Killip class and GFR with satisfactory calibration and discrimination rate."

"ABSTRAKLatar belakangPenyakit jantung Koroner (PJK) merupakan penyebab kematian yang tertinggi di dunia dan cenderung meningkat dari tahun ke tahun. Skor TIMI STEMI sudah banyak digunakan dan divalidasi sebagai prediktor kematian pasien STEMI namun belum mencakup komponen fraksi ejeksi ventrikel kiri (FEVK) dan laju filtrasi glomerulus (LFG), dan kurang optimal dalam penggunaanya.TujuanMemodifikasi skor TIMI STEMI dengan memasukkan variabel FEVK dan LFG sebagai prediktor mortalitas pada pasien STEMI dalam 30 hari di RSCM. Metode Studi kohort retrospektif terhadap 487 pasien STEMI yang di rawat di RSUPN Cipto Mangunkusumo pada periode 2004-2013. Data variabel prediktor diperoleh dari penelusuran rekam medis. Data yang didapatkan dianalisis secara bivariat dan multivariat, setelah itu dibuat formulasi baru prediktor mortalitas pasien STEMI dalam 30 hari dan akan diujikan pada seluruh data dan dinilai risiko mortalitasnya serta dibandingkan dengan skor TIMI dengan AUC (area under curve).HasilDari analisis secara bivariat dan multivariat didapat hanya dua variabel yang dapat digunakan dalam formula baru yaitu kelas killips II-IV dan LFG dengan kisaran total skor 0-4.6 Stratifikasi risiko mortalitas dalam 30 hari pada pasien STEMI adalah tinggi (total skor >3,5; 46,5%), sedang (total skor 2,5-3,5;23,2%), dan rendah (total skor <2,5;5,95%). Diskriminasi modifikasi skor TIMI STEMI dengan AUC 0.816; IK 95%; 0.756-0.875.KesimpulanModifikasi skor TIMI STEMI terdiri dari dua variabel yaitu kelas Killip dan LFG. Modifikasi ini memiliki kalibrasi dan diskriminasi yang baik sebagai prediktor mortalitas 30 hari pada pasien STEMI.

---

ABSTRACTBackgroundCoronary Heart Disease (CHD) is the leading cause of death in the world and the rate increases every year. TIMI STEMI score has been used and validated as mortality predictor for STEMI patient but unfortunately, it does not involve left ventricle ejection fraction (LVEF) and Glomerulus filtration rate (GFR), thus it is less optimal in clinical setting.ObjectiveTo modify TIMI STEMI score include LVEF and GFR as variables for 30 day mortality predictor STEMI patients in RSUPN Cipto Mangunkusumo Hospital. Methods Retrospective cohort study was done toward 487 STEMI inpatients in RSUPN Cipto Mangunkusumo Hospital in 2004-2013. Predictor variable data was obtained from medical records. The data was analyzed with bivariate and multivariate method using Cox’s Proportional Hazard Regression Model. Subsequently, formulate new predictors for STEMI patient mortality rate in 30 days. In these newly formulated predictors shall be stratified to all data and mortality risk shall be assessed and compared with current TIMI STEMI Score using area under curve (AUC).ResultsFrom bivariate and multivariate analysis, only two variables were found to have significant values for new formulation; Killip class II-IV and GFR which contribute 0.4.6 of total score value. 30 day mortality risk stratification for STEMI patient is high if total score > 3.5;46.5%, moderate if total score 2.5-3.5;23.2% and low if total score < 2.5;5.95%. Modified TIMI STEMI Score has a good discrimination rate with AUC value of 0.816 (0.756-0.875) and confidence interval (CI) 95%.ConclusionModified TIMI STEMI Score has two variables such as Killip Class and GFR. It has good calibration and discrimination for 30 day mortality predictor in STEMI patients."

"Polimorfisme CYP2C19 menurunkan metabolisme klopidogrel dan telah diketahui meningkatkan mortalitas serta kejadian kardiovaskular mayor. VerifyNow P2Y12 merupakan salah satu pemeriksaan yang secara spesifik menggambarkan fungsi platelet terhadap agen penghambat P2Y12 yang dikonsumsi. Hubungan antara polimorfisme CYP2C19 dengan TIMI flow pada populasi Asia, khususnya Indonesia, belum pernah dilakukan.Penelitian ini bertujuan untuk mengetahui hubungan antara polimorfisme CYP2C19 terhadap fungsi penghambatan platelet dan TIMI flow, serta hubungan antara fungsi penghambatan platelet dan TIMI flow.Dilakukan pemeriksaan polimorfisme CYP2C19 dengan menggunakan metode Taqman dan pemeriksaan fungsi penghambatan platelet yang diukur dengan VerifyNow P2Y12 pada 90 pasien IMA-EST yang menjalani IKPP yang memenuhi kriteria penelitian.Dari 90 subyek penelitian, studi polimorfisme genetik mengungkapkan 23,3% pasien dengan alel * 2, 11,2% dari * 3 alel pembawa, dan 1,1% membawa kedua alel. 24,4% pasien tergolong non-responder terhadap klopidogrel. Secara keseluruhan tidak terdapat hubungan secara langsung antara polimorfisme CYP2C19 dengan TIMI flow 3, namun terdapat hubungan antara polimorfisme CYP2C19 dengan penurunan fungsi penghambatan platelet (OR 4.7, p = 0.030). Indeks reaktivitas platelet >208 PRU meningkatkan risiko TIMI flow < 3 (OR 3.3, p= 0.046).Tidak terdapat hubungan secara langsung antara polimorfisme CYP2C19 dengan TIMI flow, namun pasien dengan polimorfisme CYP2C19*2 dan/atau *3 memiliki risiko untuk mengalami penurunan penghambatan fungsi platelet. Pasien yang tergolong non-responder terhadap klopidogrel ini juga berisiko untuk mendapatkan reperfusi miokard yang suboptimal. ......CYP2C19 polymorphism plays an important role in clopidogrel metabolism. The genetic factor is VerifyNow P2Y12 is an examination that specifically describes platelet function against P2Y12 inhibitors. It is unknown whether platelet reactivity measured by P2Y12 reaction unit (PRU) is affected by CYP2C19 polymorphism or predictive of TIMI flow in Asian populations, particularly in Indonesia. We sought to define whether polymorphisms on CYP2C19 genes and platelet reactivity may affect the myocardial perfusion.STEMI patients who underwent primary PCI and has received 600 mg loading dose of clopidogrel were recruited for the study. We measured platelet reactivity by VerifyNow P2Y12, high platelet reactivity was defined as > 208 PRU. Genetic polymorphisms analysis to assess the presence of CYP2C19*2 and *3 alleles on each patient were performed by Taqman method.There were 90 patients recruited for study. Genetic polymorphisms studies revealed 23.3% of patients with *2 allele, 11.2% of *3 allele carriers, and 1.1% carried both allele. 23.4% of patients were clopidogrel non-responders. Overall, there was no correlation between CYP2C19 polymorphism and TIMI flow < 3, but there was a relationship between CYP2C19 polymorphism and decreased function of platelet inhibition (OR 4.7, p = 0.030). Platelet reactivity index > 208 increased the risk of suboptimal reperfusion (OR 3.3, p = 0.046).There is no direct relationship between CYP2C19 polymorphism and TIMI flow, but patients with CYP2C19*2 and/or CYP2C19*3 had increased risk of being clopidogrel non responders. After adjusted to confounding factors, VerifyNow > 208 PRU is associated with suboptimal myocardial reperfusion."

"Latar belakang: micro-RNA saat ini telah diketahui berperan dalam patofisiologi berbagai penyakit termasuk di bidang kardiovaskular. miR-26a platelet dikaitkan dengan aktifitas platelet tinggi.Resistensi klopidogrel telah diketahui memiliki prevalensi yang cukup tinggi di populasi Asia, yang mana dapat mempengaruhi mortalitas serta kejadian kardiovaskular mayor. Hubungan antara ekspresi miR-26a platelet dengan resistensi klopidogrel begitu pula dengan TIMI flow pasca IKPP pada IMA-EST di populasi Asia, belum pernah dilaporkan. Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan antara ekspresi miR-26a platelet terhadap reaktivitas platelet dan perfusi miokardium pasca IKPP. Metode: Pada pasien IMA-EST yang menjalani IKPP dan mendapatkan terapi dosis loadingklopidogrel 600 mg, dimasukkan kedalam populasi penelitian. Kami mengukur reaktivitas platelet dengan menggunakan VerifyNow P2Y12, aktifitas platelet tinggi didefiniskan jika memiliki nilai > 208 PRU. Metode RealtimePCR Taqman dilakukan untuk analisa ekspresi miR-26a platelet. Ekspresi miR-26a platelet dan reaktivitas platelet dikorelasikan dengan TIMI flowpasca IKPP pada pasien IMA-EST. Hasil: Terdapat 100 subyek yang direkrut pada studi ini. Diantaranya, 59% menunjukkan peningkatan ekspresi miR-26a. Reaktifitas platelet meningkat pada 27 % pasien studi ini dikategorikan non-responder terhadap klopidogrel. Terdapat hubungan antara ekspresi dengan penurunan fungsi penghambatan platelet (OR 4.2, p = 0.006). Indeks reaktivitas platelet >208 PRU meningkatkan risiko TIMI flow < 3 (OR 3.3, p= 0.015). Tidak terdapat hubungan langsung antara ekspresi miR-26a platelet dan TIMI flow < 3. Kesimpulan: Pasien dengan peningkatan ekspresi miR-26a platelet memiliki risiko untuk mengalami menjadi non-responderklopidogrel. Tidak terdapat hubungan langsung antara ekspresi miR-26a platelet dan TIM flowpasca IKPP. ......Background: micro-RNA has now been known to play a role in the pathophysiology of various diseases including cardiovascular disease. Clopidogrel resistance has been known prevalent in Asian population, that may affect mortality and major cardiovascular events. The relationship between the expression of platelet miR-26a and clopidogrel resistance as well as TIMI flow post primary PCI in STEMI among Asian populations, has never been done. Objective: the aim of this study is to define whether miR-26a platelet expression has a relation with platelet reactivity and myocardial perfusion after primary PCI. Methods: STEMI patients who underwent primary PCI and has received 600 mg loading dose of clopidogrel were recruited for the study. We measured platelet reactivity by VerifyNow P2Y12, high platelet reactivity was defined as > 208 PRU. Realtime PCR by taqman method were performed to asses the expression of miR-26a platelet. miRNA-26a platelet expression and platelet reactivity were correlated with TIMI flow post primary PCI in STEMI. Hasil: there were 100 patients recruited for this study. among them, 59% of patients with high expression of miR-26a platelet. Platelet reactivity showed 27% of the patients were clopidogrel non-responders. There was a relationship between high miR-26a expression and decreased function of platelet inhibition (OR 4.2, p = 0.006). Platelet reactivity index > 208 increased the risk of suboptimal reperfusion (OR 3.3, p = 0.015). There was no direct correlation between miR-26a expression and TIMI flow < 3. Conclusion: Patients with high miR-26a platelet expression had increased risk of being clopidogrel non responders. There is no direct relationship between miR-26a platelet expression and TIMI flow after primary PCI."

"Latar Belakang. Stratifikasi risiko merupakan bagian integral dari managemen pasien sindrom koroner akut (SKA). Identifikasi pasien yang berisiko tinggi menjadi sangat penting untuk meningkatkan kewaspadaan sekaligus mengurangi tindakan berlebih terhadap pasien dengan risiko rendah. Meskipun TIMI pada STEMI dan UAPINSTEMI merupakan skor risiko yang baik dan telah divalidasi dan dipergunakan secara luas, tetapi penelitian mengenai perfonnanya belum pernah dilakukan di Indonesia. Adanya perbedaan karakteristik antara pasien SKA di Indonesia dengan populasi di negara maju dapat mempengaruhi prognosis pasien sehingga perlu dilakukan penelitian mengenai perfonna dari kedua sistem skoring tersebut. Tujuan. Menilai perfonna kalibrasi dan diskriminasi skor TIMI dalam memprediksi mortalitas 30 hari pasien STEMI dan 14 hari pasien UAPINSTEMI di Indonesia Metodologi. Studi kohort retrospektif menggunakan data rekam medis pasien SKA yang dirawat di IeeU RSeM 2003-2010 dengan metode pengambilan sampel konsekutif. Perfonna kalibrasi skor TIMI dinyatakan dengan plot kalibrasi dan uji Hosmer-Lemeshow sedangkan perfonna diskriminasi dinyatakan dengan nilai AUe. Hasil. Selama penelitian terkumpul 714 pasien STEMI dan 787 pasien UAPINSTEMI yang dirawat di IeeU RSeM. Skor TIMI STEMI mempunyai perfonna kalibrasi dan diskriminasi yang baik dengan plot kalibrasi 0,98, uji Hosmer-Lemeshow 0,93 dan nilai AUe 0,801 (Kl 95% 0,759-0,844). Perfonna kalibrasi dan diskriminasi skor TIMI UAPINSTEMI juga cukup baik dengan plot kalibrasi mencapai 0,88, uji Hosmer lemeshow 0,86 dan nilai AUe 0,727 (KI95% 0,668-0,786). Simpulan. Skor TIMI mempunyai perfonna kalibrasi dan diskriminasi yang baik dalam memprediksi mortalitas pasien SKA di Indonesia.......Background. Risk Stratification in acute coronary syndrome patients is an integral part in the management of patients. Risk stratification is important to avoid overtreatment in high risk patients, as well as undertreatment in low risk patients. Although TIMI STEMI and TIMI UAiNSTEMI are scores that have been validated and used widely, but to date no study of its appicability has been done in Indonesia. Differences in characteristic of acute coronary syndrome patients in Indonesia compared to developed countries can have influence on the prognostic of the patient hence a study is needed regarding performance of TIM I scoring system. Objectives. To obtain the calibration dan discrimination performance of TIMl risk score to predict 30 day dan 14 day mortality in STEMI and UAPINSTEMI patients in Indonesia Methods. A retrospective cohort study with consecutive sampling was done in ACS patients hospitalized in the ICCU Cipto Mangun Kusumo Hospital between the period 2003 until 2010. Calibration performance of TIM I risk score was evaluated by calibration plot and Hosmer-Lemeshow test while discrimination performance was done with A Uc. Results. A total of 714 STEMI patients and 787 UAPINSTEMI patients entered the study. TIMI STEMI risk score have a good calibration and discrimination performance with calibration plot of 0, 98, Hosmer-Lemeshow test 0,93 and AUC 0,801 (CI95% 0,759-0,844). A good calibration and discrimination performance of TIMI UAPINSTEMI risk score was observed with calibration plot of 0,88, Hosmer-Lemeshow test 0,86 and AUC 0,73 (CI 95% 0,668-0,786). Conclusion. TIM! risk score has a good calibration and discrimination performance in predicting mortality of ACS patients in Indonesia."

"Latar belakang: Hubungan antara kadar gula darah yang tinggi dan thrombolysisin myocardial infarction TIMI flow pra/pascaprosedur angioplasti primerterhadap mortalitas 1 tahun belum banyak dieksplorasi.Tujuan: Penelitian ini bertujuan untuk menentukan hubungan kadar gula darahsaat admisi dan TIMI flow pra/pascaprosedur terhadap mortalitas 1 tahun pasieninfark miokard akut disertai elevasi segmen ST IMA-EST yang menjalaniintervensi koroner perkutan primer IKPP .Metode: 856 pasien IMA-EST yang dilakukan IKPP pada Januari 2014 hinggaJuli 2016 dianalisis secara retrospektif. Cut-off yang digunakan untuk kadar guladarah tinggi pada studi ini adalah ge;169 mg/dL. Kesintasan 1 tahun dinilai denganmetode Kaplan-Meier.Hasil: Pasien dengan kadar gula darah ge;169 mg/L N=307 mempunyai proporsiTIMI flow akhir 0 ndash; 1 yang lebih tinggi [3.3 vs. 0.5 ; adjusted odds ratio OR = 5.58, 95 confidence interval CI 1.30 ndash;23.9; p=0.02] dan mortalitas 1 tahun lebih tinggi [16.3 vs. 6 ; adjusted hazard ratio HR = 1.9, 95 CI1.12 ndash;3.23, p=0.017] dibanding pasien dengan kadar gula darah rendah N=549 .TIMI flow akhir 0 ndash; 1 merupakan prediktor independen mortalitas 1 tahun HR= 7.0, 95 CI 3.23 ndash;15.15;......Background The association of high blood glucose level and Thrombolysis InMyocardial Infarction TIMI flow before after primary angioplasty with 1 yearmortality has not much been explored.Objective This study sought to determine the association of blood glucose level BGL on admission and pre post procedural TIMI flow with 1 year mortality inpatients with ST segment elevation myocardial infarction STEMI undergoingprimary percutaneous coronary intervention PCI .Methods 856 patients with STEMI and treated with primary PCI betweenJanuary 2014 and July 2016 were retrospectively analyzed. The cut off used for ahigh BGL in this study was ge 169 mg dL. Survival at 1 year was assessed byKaplan Meier method.Results Patients with BGL ge 169 mg dL N 307 had higher proportion of finalTIMI flow 0 1 3.3 vs. 0.5 adjusted odds ratio OR 5.58, 95 confidenceinterval CI 1.30 to 23.9 p 0.02 and higher 1 year mortality 16.3 vs. 6 adjusted hazard ratio HR 1.9, 95 CI 1.12 to 3.23, p 0.017 compared withlower BGL patients N 549 . Final TIMI flow 0 1 was an independent predictorof 1 year mortality HR 7.0, 95 CI 3.23 to 15.15 p"

"Pendahuluan: Intervensi koroner perkutan primer (IKPP) telah menjadi salah satu pilihan terapi pada pasien dengan infark miokard akut dengan elevasi segmen ST (IMA-EST) yang dapat menurunkan angka kematian dengan signifikan. Sebagian pasien yang menjalani IKPP mengalami kegagalan reperfusi optimal yang disebut sebagai no-reflow phenomenon (NRP). Penilaian NRP ini dapat menggunakan berbagai metode, salah satunya dengan menggunakan thrombolysis in myocardial infarction flow (TIMI flow). Kegagalan reperfusi juga meningkatkan kejadian major adverse cardiac event (MACE) pada pasien. Hiperaktivitas trombosit diketahui berperan pada patofisiologi terjadinya NRP. Nilai mean platelet volume (MPV) yang merupakan ukuran rerata volume dari trombosit dianggap dapat menggambarkan aktivasi trombosit. Penelitian ini bertujuan untuk mengetahui peran nilai MPV dengan TIMI-flow dan MACE pada pasien IMA-EST yang menjalani IKPP.Metode: Penelitian kohort retrospektif dilakukan terhadap 137 subyek dengan IMA-EST yang menjalani IKPP. Pemeriksaan MPV dilakukan pada saat masuk rumah sakit dengan alat Sysmex XN-2000. Subyek dibagi berdasarkan kelompok dengan reperfusi sub-optimal (TIMI flow < 3) dan reperfusi optimal (TIMI flow 3). Luaran klinis berupa MACE dilakukan observasi selama minimal 90 hari pasca tindakan.Hasil: Sebanyak 27.7% dan 28.9% pasien mengalami kegagalan reperfusi dan MACE. Tidak terdapat hubungan antara nilai MPV pada saat masuk rumah sakit dengan kegagalan reperfusi dan kejadian MACE 90 hari pada pasien IMA-EST di Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita.Kesimpulan: Nilai MPV tidak dapat digunakan dalam memprediksi kegagalan reperfusi dan kejadian MACE pada pasien IMA-EST yang menjalani IKPP.

---

Introduction: Primary percutaneous coronary intervention (PCI) has become one of the treatment options in patients with acute myocardial infarction with ST segment elevation (STEMI) which can significantly reduce mortality. In some patients who undergo primary PCI experience failure of optimal reperfusion called the no-reflow phenomenon (NRP). NRP assessment can use various methods, one of them using thrombolysis in myocardial infarction flow (TIMI flow). Failure of reperfusion also increases the incidence of major adverse cardiac events (MACE) in patients. Platelet hyperactivity is known to play a role in the pathophysiology of NRP. The mean platelet volume (MPV) which is a measure of the average volume of platelets is considered to be able to describe platelet activation. This study aims to determine the role of MPV values ​​with TIMI-flow and MACE in STEMI patients undergoing primary PCI.Methods: A retrospective cohort study was conducted on 137 STEMI patients who underwent primary PCI. MPV examination is performed at hospital admission with Sysmex XN-2000. Subjects were divided into groups with sub-optimal reperfusion (TIMI flow <3) and optimal reperfusion (TIMI flow 3). Clinical outcomes in the form of MACE were observed for at least 90 days post-treatment.Result: 27.7% and 28.9% of patients experienced failure of reperfusion and MACE, respectively. There is no relationship between the MPV value at hospital admission with failure of reperfusion and the incidence of 90-day MACE in IMA-EST patients at the Harapan Kita Heart and Vascular Hospital.Conclusion: MPV values ​​cannot be used in predicting reperfusion failure and MACE events in STEMI patients undergoing primary PCI."

"Latar Belakang: Sindrom koroner akut (SKA) dapat didefinisikan sebagai aliran darah yang tidak cukup ke miokardium dan salah satu penyakit kardiovaskular yang paling umum di Indonesia yang mempengaruhi 143.000 orang. Skor risiko TIMI adalah penilaian stratifikasi risiko yang dapat menentukan prognosis pasien dan memengaruhi opsi terapi. Tes fungsi ginjal dikaitkan dengan keparahan hipoksia dan faktor-faktor lain yang berkontribusi dalam SKA dan tidak termasuk dalam skor risiko TIMI. Penelitian ini bertujuan untuk melihat hubungan antara tes fungsi ginjal dan skor risiko TIMI pada pasien SKA. Metode: Penelitian ini menggunakan model analitik cross-sectional menggunakan pengumpulan data rekam medis yang meliputi serum kreatinin, serum ureum, dan skor risiko TIMI yang diperoleh dari Rumah Sakit Nasional Cipto Mangunkusumo. 117 sampel diperoleh yang kemudian dianalisis dengan uji chi-square. Hasil: Uji fungsi ginjal terbukti secara signifikan terkait dengan Skor Risiko TIMI. Serum kreatinin dikaitkan dengan skor risiko TIMI (p = 0,0407) serta serum ureum juga dikaitkan dengan skor risiko TIMI (p = 0,036). Kesimpulan: Terdapat hubungan antara serum kreatinin dan serum ureum yang tinggi dengan tingginya skor risiko TIMI.......Background: Acute coronary syndrome (ACS) is defined as insufficient blood flow to the myocardium and one of the most common cardiovascular disease in Indonesia affecting 143.000 people. TIMI risk score is risk stratification assessment that can determine the prognosis of the patient and affect therapy options. Renal function test is associated with hypoxia severity and other contributing factors in ACS which is not included in TIMI risk score. This research aims to see the association of renal function test and TIMI risk score in ACS patients. Method: The research uses analytical cross-sectional model using medical records data collection which encompasses serum creatinine, serum ureum, and TIMI risk score obtained from Cipto Mangunkusumo National Hospital. 117 samples are obtained which is then analysed using chi-square test. Results: Renal function test proved to be significantly associated with TIMI Risk Score. Serum creatinine is associated with TIMI risk score (p=0,0407) as well as serum ureum is also associated with TIMI risk score (p=0,036). Conclusion: There is an association between high serum creatinine and high serum ureum with TIMI risk score in ACS patients."

"ABSTRAKLatar belakang: Salah satu faktor yang dicurigai berperan dalam mekanisme resisensi klopidogrel adalah faktor epigenetik seperti metilasi DNA. Individu dengan resistensi klopidogrel ini memiliki kecenderungan untuk mengalami luaran kardiovaskular yang lebih buruk. Nilai TIMI flow pasca IKPP telah diketahui berkaitan dengan luaran klinis pada pasien IMA-EST. Sampai saat ini belum ada penelitian yang menghubungan antara metilasi gen P2Y12 dengan penghambatan fungsi platelet dan nilai TIMI flow pasca IKPP pada pasien IMA EST. Tujuan: Untuk mengetahui hubungan antara metilasi gen reseptor P2Y12 terhadap fungsi penghambatan platelet dan nilai TIMI flow pasca IKPP pada pasien IMA EST. Metode: Sebanyak 118 pasien IMA-EST yang menjalani IKPP dan mendapatkan terapi klopidogrel dimasukkan kedalam populasi penelitian. Dilakukan pemeriksaan VerifyNow P2Y12 dan pemeriksaan metilasi P2Y12. Selanjutnya dilakukan analisis hubungan antara metilasi P2Y12 dengan nilai Verifynow P2Y12 dan TIMI flow pasca IKPP. Hasil: Dari seluruh subyek, 22% diantaranya termasuk klopidogrel nonresponder dan 30% memiliki nilai TIMI flow kurang dari 3. Terdapat 48% subyek yang tidak mengalami metilasi dan 19% subyek mengalami metilasi sempurna pada gen P2Y12. Tidak terdapat hubungan bermakna antara metilasi P2Y12 dengan nilai Verifynow P2Y12 dan TIMI flow pasca IKPP. Nilai Verifynow P2Y12 yang tinggi berhubungan dengan TIMI flow kurang dari 3 pasca IKPP (p=0,043). Kesimpulan: Tidak terdapat hubungan bermakna antara pola metilasi gen P2Y12 dengan penghambatan fungsi platelet dan nilai TIMI flow pasca IKPP. Pasien yangnon-responder terhadap klopidogrel berisiko untuk mendapatkan reperfusi miokard yang suboptimal.

---

ABSTRACTBackground: Mechanism of clopidogrel resistance is not well understood yet. In the other hand, epigenetic modifications such as DNA methylation, are suspected to play role in clopidogrel resistence. Subject with high on treatment clopidogrel reactivity show worsen cardiovascular outcome. Meanwhile, TIMI flow after reperfusion are known to be related with poor outcome. Study that evaluate the relationship between methylation of P2Y12 gene with Platelet Reactivity and TIMI-flow after Primary Percutaneous Coronary Intervention (PPCI) in Patients With Acute ST-segment Elevation Myocardial Infarction in South East Asia Population has never been done. Objectives: to define whether methylation of P2Y12 gene and platelet reactivity may affect the myocardial perfusion after PPCI. Methods: There were 118 of STEMI patients who underwent PPCI and had received clopidogrel were recruited for the study. We measured platelet reactivity using Verifynow P2Y12 and Methylation of P2Y12 gene. The relationship among variables are assessed using statistic method. Results: Among 118 subject, 22% are clopidogrel nonresponder and 30% had TIMI flow less than 3. Median of Methylation degree was 15% with 48% subject were unmethylated, 19% subject had 100% methylation. There are no relationship between methylation of P2Y12 gene with platelet reactivity and TIMI flow after PPCI among subjects. The value of Verifynow P2Y12 more than 208 were related TIMI flow less than 3 after PPCI (p=0,043). Conclusion: There are no relationship between methylation of P2Y12 gene with platelet reactivity and TIMI flow after PPCI among subjects. Clopidogel nonresponder subjects were more likely to have suboptimal reperfusion after PPCI"